Altre lingue Immunovia AB

Azioni

IMMNOV

SE0006091997

Tempo differito Nasdaq Stockholm Altri mercati azionari 12:59:40 30/04/2024			Variaz. 5gg	Var. 1 gen.
2,03 ^SEK	-6,24%		+6,06%	+14,56%

29/04	Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024
29/04	Immunovia nomina Lisa Ford direttore del laboratorio clinico	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director	29/04
Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina	29/04
Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina	29/04
Immunovia Appoints Lisa Ford as Clinical Laboratory Director	29/04
Immunovia publishes the annual report for 2023	29/04
Immunovia Publishes Interim Report for January-March 2024	29/04
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Invitation to Immunovia's Q1 presentation	23/04
Immunovia announces updated financial calendar	22/04
Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test	22/04
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	22/04
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	09/04
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study	09/04
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	09/04
Immunovia announces updated financial calendar	12/03
Immunovia Publishes Full Year Report for 2023	21/02
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Invitation to Immunovia's Q4 presentation	14/02
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs	31/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Immunovia AB

Azioni

IMMNOV

SE0006091997

Altre lingue

Filtri